Jonathan Heaney Consultant Rheumatologist Newcastle

Jonathan Heaney Consultant Rheumatologist Newcastle – Expert in Connective Tissue Diseases

Jonathan Heaney Consultant Rheumatologist Newcastle brings years of specialised experience in managing complex autoimmune and connective tissue conditions. Based at the renowned Freeman Hospital, Dr Heaney delivers patient-centred care backed by clinical expertise and research.

Consultant Rheumatologist With a Proven Track Record

After completing his specialist training in Edinburgh in 2012, Dr Heaney began his consultant career at Sunderland Royal Hospital. He then joined Freeman Hospital in 2017. Since then, he has continued to serve patients across Newcastle and the North East with dedication and skill.

Jonathan Heaney Consultant Rheumatologist Newcastle – Specialising in Inflammatory Connective Tissue Diseases

At Freeman Hospital, Dr Heaney leads inflammatory connective tissue disease clinics. His special interest in vasculitis helps patients receive early and accurate diagnoses. He is a key member of the North East Regional CTD and Vasculitis MDT, where he collaborates with fellow specialists to deliver integrated care.

Supporting Fast Access to Treatment

Dr Heaney also contributes to Newcastle’s Giant Cell Arteritis Fast Track Service. This program ensures patients receive prompt assessment and treatment, reducing the risk of complications. Additionally, he runs general rheumatology clinics, managing a wide spectrum of autoimmune and musculoskeletal disorders.

Collaborative, Multi-Disciplinary Approach

Working alongside colleagues in Respiratory, Dermatology, Renal, ENT, and Neurology, Dr Heaney adopts a holistic approach to patient care. This collaboration ensures each patient benefits from a full-spectrum evaluation and tailored treatment plan.

Active in Clinical Research and Innovation

Beyond patient care, Dr Heaney plays an active role in clinical research. He regularly recruits patients into national and international trials focused on vasculitis, inflammatory arthritis, and connective tissue diseases. These studies aim to advance treatment options and improve long-term outcomes.